Biotech News
Vertex Pharmaceuticals Secures FDA Approval for JOURNAVX, a Non-Opioid Pain Treatment
The U.S. Food and Drug Administration (FDA) has approved Vertex Pharmaceuticals’ JOURNAVX (suzetrigine), a non-opioid, highly selective NaV1.8 pain signal inhibitor, for the treatment of adults with moderate-to-severe acute pain. The approval marks the first new class of pain medicine
31 January 2025